Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT01153100 | Effectiveness of Adding Subcutaneous Long-acting Glargine to Insulin Drip Therapy Compared With Standard Insulin Drip Therapy | PHASE1 | COMPLETED | 60 | — | — | Apr 1, 2010 | Feb 1, 2012 | Nov 1, 2019 | 1 | United States |
| Arm | Type | Description |
|---|---|---|
| Standard insulin drip therapy | NO_INTERVENTION | Standard insulin drip therapy |
| Insulin drip and glargine | ACTIVE_COMPARATOR | Insulin drip and glargine 0.25 units per kg body weight |
| Name | Type | Description |
|---|---|---|
| Glargine | DRUG | Glargine 0.25 units per kg body weight given every 24 hours while patients are receiving intravenous (IV) standard insulin drip therapy |
Inclusion Criteria: * Diabetic ketoacidosis (DKA) and hyperglycemic hyperosmolar non-ketotic states, hyperglycemia with severe illness, pre- and postoperative states, nothing by mouth (NPO), as well as gastric (tube feeding) and parenteral nutrition requiring insulin drip. * Patients with type 1 an...